HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
HLS Therapeutics Dividend Announcement
• HLS Therapeutics announced a quarterly dividend of C$0.05 per ordinary share which will be made payable on 2023-06-15. Ex dividend date: 2023-04-27
• HLS Therapeutics annual dividend for 2023 was C$0.10
• HLS Therapeutics's trailing twelve-month (TTM) dividend yield is -%
HLS Therapeutics Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2023-04-27 | C$0.05 | quarterly | 2023-06-15 |
2023-01-30 | C$0.05 | quarterly | 2023-03-15 |
2022-10-28 | C$0.05 | quarterly | 2022-12-15 |
2022-07-28 | C$0.05 | quarterly | 2022-09-15 |
2022-04-28 | C$0.05 | quarterly | 2022-06-15 |
2022-01-27 | C$0.05 | quarterly | 2022-03-15 |
2021-10-28 | C$0.05 | quarterly | 2021-12-15 |
2021-07-29 | C$0.05 | quarterly | 2021-09-15 |
2021-04-29 | C$0.05 | quarterly | 2021-06-15 |
2021-01-28 | C$0.05 | quarterly | 2021-03-15 |
2020-10-29 | C$0.05 | quarterly | 2020-12-15 |
2020-07-30 | C$0.05 | quarterly | 2020-09-15 |
2020-04-29 | C$0.05 | quarterly | 2020-06-15 |
2020-01-30 | C$0.05 | quarterly | 2020-03-13 |
2019-10-30 | C$0.05 | quarterly | 2019-12-13 |
2019-07-30 | C$0.05 | quarterly | 2019-09-13 |
2019-04-29 | C$0.05 | quarterly | 2019-06-14 |
2019-01-30 | C$0.05 | quarterly | 2019-03-15 |
HLS Therapeutics Dividend per year
HLS Therapeutics Dividend growth
HLS Therapeutics Dividend Yield
HLS Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing HLS Therapeutics stock? Use our calculator to estimate your expected dividend yield:
HLS Therapeutics Financial Ratios
HLS Therapeutics Dividend FAQ
Other factors to consider when evaluating HLS Therapeutics as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy HLS Therapeutics stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: HLS Therapeutics's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, HLS Therapeutics publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, HLS Therapeutics distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from HLS Therapeutics are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: HLS Therapeutics sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, HLS Therapeutics distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: HLS Therapeutics declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of HLS Therapeutics's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review HLS Therapeutics's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.